

## Commercial/Healthcare Exchange PA Criteria Effective: October 8, 2020

**Prior Authorization:** Semglee

**Products Affected:** Semglee (insulin glargine) Pen, Semglee (insulin glargine) vial, Semglee-yfng Pen, Semglee-yfng vial, Insulin glargine-yfng Pen, Insulin glargine-yfng vial, Insulin glargine 100 units/mL vial and Insulin glargine 100 units/mL pen

**Medication Description:** The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis.

**Covered Uses:** Improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

**Exclusion Criteria:**

1. Patients with hypersensitivity to insulin glargine
2. Use during episodes of hypoglycemia

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried and failed

**Age Restrictions:**

Type 1 diabetes mellitus: 6 years of age or older  
Type 2 diabetes mellitus: 18 years of age or older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:**

**Diabetes mellitus (type 1 or type 2)**

- A. Patient has a diagnosis of type 1 or type 2 diabetes mellitus; **AND**
- B. Patient has a documented intolerance to, contraindication, or treatment failure to **ALL** the following long acting insulins:
  - i. Lantus (Solostar, vial)
  - ii. Levemir (Flextouch, vial)
  - iii. Toujeo (Max Solostar, Solostar)
  - iv. Tresiba (Flextouch, vial)

**References:**

1. Semglee (insulin glargine) [prescribing information]. Morgantown, WV: Mylan; June 2020.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1.	New Policy	New Policy	All	10/08/2020
2.	Update	Updated policy to include new Semglee products (Semglee- yfgn and Insulin glargine-yfgn) vial and pen	Products Affected	11/12/2021
3.	Update	Added Insulin glargine	Products Affected	6/27/2022